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The World Health Organization developed a set of human immunodeficiency virus drug resistance (HIVDR)
early warning indicators (EWIs) to assess antiretroviral therapy clinic and program factors associated with
HIVDR. EWIs are monitored by abstracting data routinely recorded in clinical records, and the results enable
clinics and program managers to identify problems that should be addressed to minimize preventable
emergence of HIVDR in clinic populations. As of June 2011, 50 countries monitored EWIs, covering 131 686
patients initiating antiretroviral treatment between 2004 and 2009 at 2107 clinics. HIVDR prevention is
associated with patient care (appropriate prescribing and patient monitoring), patient behavior (adherence),
and clinic/program management efforts to reduce treatment interruptions (follow up, retention on first-line
ART, procurement and supply management of antiretroviral drugs). EWIs measure these factors and the results
have been used to optimize patient and population treatment outcomes.
The rapid scale-up of antiretroviral therapy (ART) for
human immunodeficiency virus (HIV) in resource-
limited settings (RLSs) is an international healthcare
priority. By December 2010, 6.6 million people living
with HIV in low- and middle-income countries were
receiving ART, representing an increase of.1.4 million
people from December 2009 and a 22-fold increase
in 10 years [1]. The public health approach to scaling
up ART in RLSs includes standardized and simplified
treatment regimens consistent with international stand-
ards and appropriate to local circumstances [2].
Treatment of millions of HIV-infected patients will
inevitably be accompanied by the emergence and
transmission of HIV drug resistance (HIVDR). The
human and financial implications of HIVDR are
significant; HIVDR limits treatment options and
necessitates switching to second-line regimens that
produce more long-term toxicity [3–6]. Moreover,
the annual cost of a second-line protease inhibitor–
based regimen is 4–8 times higher than that of cur-
rently recommended first-line nonnucleoside reverse
transcriptase inhibitor (NNRTI)–based regimens [7].
Although the proportion of patients on second-line
ART is currently small in most RLSs (,3%) [8], the
number of patients requiring second-line drugs will
increase.
In most RLSs, HIVDR testing is neither routinely
available nor recommended for individual patient man-
agement. Genotyping is expensive and complex, and the
alternative regimens currently available in most RLSs
limit possible treatment options. However, the mon-
itoring of patient and clinic factors associated with the
emergence of preventable HIVDR is comparatively
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inexpensive and can be used to identify these factors and reduce
their harmful consequences [9, 10].
The World Health Organization (WHO) developed a set of
HIVDR early warning indicators (EWIs) that assess ART, pa-
tient, clinic, and program factors associated with HIVDR
emergence and provide targets for optimal functioning of clinics
and programs. Emergence of HIVDR in treated populations is
associated with factors related to patient care (appropriate pre-
scribing and viral load [VL] suppression at 12 months), patient
behavior (adherence), and clinic-level and program manage-
ment (follow-up, retention on first-line ART, and procurement
and supply management of antiretrovirals [ARVs]). HIVDR
EWIs monitor these factors and provide evidence for action to
be taken at clinic or program levels to optimize population
treatment outcomes [11]. WHO HIVDR EWIs and corre-
sponding targets are listed in Table 1.
EWI 1 assesses prescribing practices. Four of the 7 EWIs serve
as proxies for treatment interruptions: EWI 2 (patient loss to
follow-up), EWI 4 (on-time ARV pickups), EWI 5 (on time
ART clinic appointment keeping), and EWI 6 (ARV stock-
outs). EWI 3 (retention on first-line ART at 12 months) as-
sesses clinic and program management functioning, and EWI 7
monitors ART adherence using standardized measures such as
pill count or visual analogue scale. EWI 8 measures HIV RNA
suppression (VL ,1000 copies/mL) at 12 months.
Prescribing practices are closely associated with the emer-
gence of HIVDR. For example, the prescribing of mono- and
dual-ART are treatment approaches that are not recommended
by international guidelines due to the rapid selection of drug-
resistant HIV [12–16]. Likewise, inappropriate dosing in
pediatric populations may lead to insufficient drug pressure
to effect VL suppression, leading to the selection of drug-
resistant virus.
A challenge to long-term ART programmatic success is
maintaining populations of patients on ART without treatment
interruptions. Treatment interruptions may arise due to poor
patient adherence or may occur as an unintended conse-
quence of ARV supply interruption at ART clinic dispensaries
[17–20]. Notably, ART interruptions of $48 hours in patients
receiving NNRTI-based regimens are associated with the selec-
tion of drug-resistant HIV [19, 21, 22]. Pharmacy-based esti-
mates of adherence such as on-time ARV pickups predict
virological and HIVDR outcomes [23–26]. Significantly, ARV
stockouts are linked to the emergence of HIVDR in adult and
pediatric populations [17–20, 23, 27, 28].
By routinely monitoring ART prescribing practices, loss to
follow-up, retention on first-line ART, on-time drug pickups
and appointment keeping, ARV supply continuity, and VL
suppression of ART patients, clinics and programs may make
necessary adjustments to minimize factors associated with
HIVDR emergence.
EWIs are monitored using a standardized methodology that
first samples patients consecutively according to ART start date,
depending on the total number of patients at each site starting
ART during the target year or years and then abstracts the data
from medical or pharmacy records on these patients [9, 11].
WHO recommends standardized EWI definitions and targets,
supported by abstraction tools. National ART programs select
HIVDR EWIs for monitoring based on national priorities and
the feasibility of data abstraction. EWI results are generalizable
to the population of patients starting or receiving ART at the
clinic during the year assessed. Because data routinely recorded
in patients’ medical and pharmacy records are used to calculate
HIVDR EWIs, EWI monitoring is easily integrated into existing
national ART monitoring and evaluation programs.
WHO recommends that EWIs be monitored annually at all
ART clinics within a country or at a large number of repre-
sentative clinics [9, 11]. HIVDR EWIs are recommended for
both adult and pediatric populations and should be moni-
tored separately even if both pediatric and adult patients are
treated at the same clinic. Data abstraction is identical in both
populations except that pediatric EWIs monitor the appro-
priate dosing for weight and the availability of pediatric ARV
formulations.
In order to minimize potential bias associated with clinic self-
reports, current WHO EWI guidance recommends that in the
Table 1. World Health Organization HIV Drug Resistance Early
Warning Indicators and Associated Targets
EWI EWI Target (%)
1. Prescribing practices (% of initial ART
prescriptions congruent with national/
WHO guidelines)
100
2. Loss to follow-up (% of patients lost to
follow-up at 12 mo)
#20
3. Retention on first-line ART (% of patients
retained on first-line ART at 12 mo)
$70
4. On-time pill pickup (% of patients with
100% on-time drug pickups during the
first 12 mo of ART, or during a specified
time period)
$90
5. On-time clinic appointment keeping
(% of patients who attended all
appointments on time during the first
12 mo of ART, or during a specified
time period)
$80
6. Drug supply continuity (% of clinics with
antiretroviral drug supply continuity during
a 12-mo period)
100
7. Adherence as measured by pill count
(% patient adherence to ARVs by pill
count or other standardized measure)
$90
8. Viral load suppression 12 mo after ART
initiation (% of patients with viral load
,1000 copies/mL at 12 mo)
$70
Abbreviations: ART, antiretroviral therapy; EWI, early warning indicator;
HIV, human immunodeficiency virus; WHO, World Health Organization.
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first 1–2 years of EWI monitoring, data abstraction and analysis
be performed by teams coordinated by a country’s Ministry of
Health and not by staff from the clinics that are being monitored
[11]. Once analyzed, clinic-specific results are communicated
to participating clinics through supervisory visits or national
workshops. Annually, EWI results are disseminated nationally
and globally through WHO.
METHODS
Adult and pediatric EWI monitoring results are reported yearly
to WHO by participating countries from 5 WHO regions: the
African region; the Pan-American region, which includes
Latin America and the Caribbean (LAC); the Southeast Asia
region; the Western Pacific region; and the European region.
The results were analyzed by region and by the year of
treatment initiation of the cohort surveyed. For regional
analyses, the total number of clinics meeting the target for each
EWI was calculated as a percentage of all the clinics monitored
in the region. For analyses based on year, cohorts bridging
more than 1 year were reported in the latest cohort start year.
We calculated 2-sided 95% exact binomial confidence intervals
using SAS software, version 9.2 (SAS Institute, Cary, North
Carolina). The countries in the Western Pacific and Southeast
Asia regions were combined. Data from the Ukraine were ex-
cluded from regional analyses, as the Ukraine was the sole
country monitoring EWIs in Europe. Trends over time within
countries and regions were not assessed owing to different
clinics and countries reporting data each year.
RESULTS
As of June 2011, a total of 50 countries reported results from
cohorts of patients initiating ART during 2004–2009, assessing
131 686 patients at 2107 ART clinics (Africa: 907 clinics in 25
countries; Asia: 1048 clinics in 6 countries; LAC: 148 clinics in 18
countries; and Europe: 4 clinics in 1 country).
Adult EWIs
Figure 1 shows the number of clinics monitoring each EWI in
adults. EWIs 1–3 (prescribing practices, loss to follow-up, and
retention on first-line ART at 12 months, respectively) were
monitored at 93%–99% of clinics. EWI 5 (on-time appointment
keeping) was monitored in 65% of clinics, and EWIs 4 and 6
(on-time ARV pickup and ARV supply continuity, respectively)
at a minority of clinics (17% and 34%, respectively). EWI 8 (VL
suppression at 12 months) was monitored in only 2% of clinics.
EWI 7 (adherence assessed through pill count) was monitored
by only 2 countries (,1% of clinics) and the data for EWI 7 were
excluded in these analyses. Adult EWI results by country and by
year are reported in Supplementary Table 1A. Results by region
and year of adult cohort ART starting with 95% confidence
intervals are reported in Table 2.
The percentages of clinics meeting WHO targets by EWI and
region are presented in Figure 2. Aggregate data are summarized
below.
d EWI 1 (prescribing of ART congruent with national/WHO
guidelines): globally, 75% of clinics monitored met the target of
100% of patients receiving prescriptions for ART congruent
Figure 1. Number of clinics monitoring early warning indicators (EWIs) among adult patients by region, 2004–2009.
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with national/WHO guidelines. Among participating clinics,
74% in Africa, 80% in Asia, and 46% in LAC met this target.
d EWI 2 (loss to follow-up at 12 months): overall, 69% of
clinics met the target of #20% patients lost to follow-up at
12 months with 59%, 75%, and 85% of clinics meeting the
target in Africa, Asia, and LAC, respectively.
d EWI 3 (retention on first-line ART): 67% of clinics met the
target of $70% of patients retained on first-line ART at
12 months with 61%, 72%, and 71% of clinics meeting the
target in Africa, Asia, and LAC, respectively.
d EWI 4 (on-time drug pickup): 17% of 352 clinics met the
target of$90% of patients picking up their ARV on time 100%
of the time with 15%, 0%, and 57% of clinics meeting the target
in Africa, Asia, and LAC, respectively.
d EWI 5 (on-time appointment keeping): globally, 58%
of clinics met the target of $80% of patients keeping 100% of
clinical appointments on time with 43%, 64%, and 15% of
clinics meeting the target in Africa, Asia, and LAC, respectively.
d EWI 6 (ARV supply continuity): 65% of clinics met the EWI
6 target of 100% ARV supply continuity with 63%, 89%, and
51% of clinics meeting the target in Africa, Asia, and LAC,
respectively.
d EWI 8 (VL suppression ,1000 copies/mL at 12 months):
only 6 countries from all regions reported this indicator. Of the
46 clinics reporting, 85% of clinics met the target of $70% of
patients showing VL suppression 12 months after ART
initiation, with 96% and 73% of clinics meeting the target in
countries reporting from Africa and LAC, respectively.
Pediatric EWIs
In cohorts of patients starting ART between 2006 and 2009,
6 countries monitored pediatric EWI at 359 clinics (Africa:
21 clinics in 2 countries; Asia: 334 clinics in 3 countries; LAC:
4 clinics in 1 country). Of these 359 clinics, 296 (82%) were in
Thailand. All 6 countries monitored EWIs 1 and 3; 5 monitored
EWI 2; 2 countries monitored EWI 6, and no country moni-
tored EWI 4 or 8.
Results of pediatric EWI monitoring are presented in
Supplementary Table 1B by country and by year. For EWI 1,
the percentages of clinics meeting the target ranged from 50%
(in Zimbabwe) to 100% (in Cambodia and Botswana); for
EWI 2, from 74% (Thailand) to 100% (Cambodia, Vietnam,
Zimbabwe); for EWI 3, from 50% (Zimbabwe) to 100%
(Dominican Republic, Vietnam); for EWI 5, from 67%
(Thailand) to 75% (Cambodia, Vietnam); and for EWI 6,
from 88% (Cambodia) to 100% (Dominican Republic).
DISCUSSION
Emergence of HIVDR in treated patients increases the cost of
ART in all countries. In low- and middle-income settings, this
burden can limit the pace of ART scale-up and the number of
patients receiving treatment. For a country providing services
for a growing number of treatment-eligible patients, the annual
cost of providing second-line ART to a single patient equals the
cost of maintaining 3–4 people on first-line ART [7]. For
populations being treated in these settings, drug resistance se-
verely restricts the already limited regimen options.
The number of adult patients on second-line ART continues
to be low in most regions, with the exception of LAC, where
nearly 28% were on second-line and 3% were on salvage
regimens in 2010 [8]. However, it is not clear to what extent
the limited capacity of countries to timely diagnose treatment
failure or the limited availability and high cost of second-line
drugs contribute to continued small percentages of patients on
second-line treatment in most countries.
As ART roll-out continues, increased rates of HIVDR may
occur. Recent WHO data document moderate (5%–15%) levels
of transmitted HIVDR in specific geographic regions [29],
underscoring the importance of addressing and minimizing
HIVDR at both the national program and clinic levels.
Analysis of HIVDR EWI monitoring in 50 countries led to
many valuable observations. Most countries, except in LAC, had
relatively few clinics that did not meet the 100% target for
prescribing first-line regimens congruent with national/
WHO guidelines (EWI 1). EWI 1 assesses a clinic’s use of
simplified highly active first-line combination regimens that
support viral suppression. Treatment with ,3 drugs or with
a nonpotent 3-drug regimen can lead to virologic failure
[12, 14, 16] and HIVDR [15, 30]. An unintended limitation of
this indicator was that even though first-line regimens that
contained protease inhibitors, or under certain circumstances,
tenofovir, would not have selected for HIVDR, they were
classified as inappropriate if not recommended by national
guidelines. For example, nonstandard prescribing practices
reported in LAC countries may have resulted from a more
individualized ART approach rather than a public health ap-
proach based on standardized regimens [31].
Globally, 69% of clinics that were assessed met the targets
for retention on first-line ART at 12 months. Retention of
patients on first-line ART at 12 months after ART initiation
(EWI 3) is important in RLS because many clinics have only
1 second-line regimen available, and no salvage regimens.
Thus, optimizing patient adherence to first-line ART and
minimizing inappropriate switching to second-line ART
during the first 12 months is critical to the long-term success
of population-based ART.
Only 21 of 50 countries (42%) had records enabling ab-
straction of on-time ARV pickups (EWI 4) and many countries
performed poorly on this indicator: in countries reporting
from Africa, only 15% of 321 adult clinics met the target; in
Asia, 0% of 10 adult clinics met the target; and in Latin
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Table 2. Number of Clinics Monitored and the Percentage Meeting the Target by Early Warning Indicator, Region, and Year of Adult Cohort Antiretroviral Therapy Start
Region
Year
Cohort
Started
ART
EWI 1
(Prescribing
Practices),
No. (%) 95% CI
EWI 2
(Loss to
Follow-up),
No. (%) 95% CI
EWI 3
(Retention on
First-Line
ART 12 Mo),
No. (%) 95% CI
EWI 4
(On-Time
ARV
Pickup),
No. (%) 95% CI
EWI 5
(On-Time
Clinic
Appointment
Keeping),
No. (%) 95% CI
EWI 6
(Drug
Supply
Continuity),
No. (%) 95% CI
EWI 8
(Viral Load
Suppression),
No. (%) 95% CI
Africa 2005–2006 193 80.9–91.0 191 74.3–86.0 191 47.1–61.7 10 .3–44.5 55 09.1–30.9 147 69.2–83.4
(86.5) (80.6) (54.5) (10.0) (18.2) (76.9)
6 countries 6 countries 6 countries 1 country 3 countries 3 countries
Asia 2005–2006 22 65.1–97.1 22 84.6–100 22 65.1–76.4 4 .0–60.2 18 52.4–93.6 18 65.3–98.6
(86.4) (100) (86.4) (00.0) (77.7) (88.9)
2 countries 2 countries 2 countries 2 countries 1 country 1 country
LAC 2004–2006 18 45.7–90.3 21 83.9–100 2 21.8–66.0 13 54.6–98.1 11 .0–28.5 18 21.5–69.2 1 2.5–100
(72.2) (100) (42.9) (84.6) (00.0) (44.4) (100)
5 countries 8 countries 9 countries 2 countries 1 country 8 countries 1 country
Africa 2007 309 70.2–80.0 281 58.5–70.0 285 65.6–76.4 120 16.1–31.9 139 16.3–30.9 226 52.2–65.8
(75.4) (64.4) (71.2) (23.3) (23.0) (59.3)
14 countries 13 countries 12 countries 7 countries 4 countries 10 countries
Asia 2007 47 79.6–97.0 47 79.6–97.6 47 66.7–90.9 4 .0–60.2 45 58.1–85.4 41 70.8–94.4
(91.5) (91.5) (80.9) (00.0) (73.3) (85.4)
3 countries 3 countries 3 countries 1 country 3 countries 3 countries
LAC 2007 41 32.9–64.9 41 65.1–91.2 42 52.9–82.4 1 .0–97.5 1 .0–97.5 32 26.4–62.3 7 29.2–100
(48.8) (80.5) (69.1) (00.0) (00.0) (43.8) (100)
11 countries 12 countries 9 countries 1 country 1 country 4 countries 3 countries
Africa 2008 180 77.7–88.9 174 39.5–54.8 167 21.8–66.0 125 06.9–19.0 41 26.3–57.9 124 48.1–66.1
(83.9) (47.1) (53.3) (12.0) (41.46) (57.3)
12 countries 11 countries 10 countries 12 countries 4 countries 8 countries
Asia 2008 943a 76.0–81.4 941a 69.5–75.3 943a 68.0–73.9 943a 59.9–66.2 41 80.1–98.5
(78.8) (72.5) (71.1) (63.1) (92.7)
2 countries 2 countries 2 countries 2 countries 1 country
LAC 2008 50 33.7–62.6 43 64.0–90.0 44 52.4–81.4 5 .0–52.2 5 .5–71.6 27 53.7–89.0 11 16.8–76.2
(48.0) (79.1) (68.2) (00.0) (20.0) (74.1) (45.5)
13 countries 9 countries 13 countries 2 countries 2 countries 7 countries 4 countries
Africa 2009 225 45.7–59.1 148 27.5–43.4 220 51.4–64.8 66 01.0–12.7 74 92.7–99.9 40 31.5–63.9 24 78.9–99.9
(52.4) (35.1) (58.2) (04.6) (98.7) (47.5) (95.8)
7 countries 5 countries 5 countries 4 countries 1 country 1 country 1 country
Asia 2009 36 90.26–100 33 84.6–100 33 75.7–98.1 2 .0–84.2 31 59.9–66.2
(100) (100) (90.9) (00.0) (64.5)
2 countries 1 country 2 countries 2 countries 1 country
LAC 2009 32 09.3–40.0 11 58.7–99.8 25 86.3–100 2 01.3–98.7 3 09.4–99.2 9 02.8–60.0 3 29.2–100
(21.9) (90.9) (100) (50.0) (66.7) (22.2) (100)
7 countries 6 countries 5 countries 1 country 2 countries 4 countries 2 countries
S284
d
C
ID
2012:54
(S
u
p
p
l
4)
d
B
en
n
ett
et
al
America and the Caribbean, 57% of 21 adult clinics met the
target. It is important that barriers to on-time ARV pickups,
such as the cost of services at the clinic [20, 28, 32–37],
transportation availability [38–40], and long waiting times at
the pharmacy be addressed [38].
Clinical appointment keeping (EWI 5) has been correlated
with other measures of ART adherence [38, 41]. Only 16
countries monitored this indicator for adults, and only 3, all
in Asia, monitored it for pediatric patients. Low percentages
of pediatric clinics met the EWI 5 target. Clinic appointments
are not recorded in records in many clinics, limiting the
country’s ability to monitor this EWI.
Ideally, clinics should follow up patients who miss ap-
pointments (EWI 5) within 48 hours. Although the ability
to track defaulters is crucial to ensuring uninterrupted ART,
and will become even more important as more individuals
are started on ART at higher CD4 cell counts, most clinics do
not have the resources for tracking and linking patients back
into treatment. Examples of country efforts to improve patient
tracing are described below.
The extent to which stockouts of routinely used ARVs (EWI
6) were reported is worrisome in all regions although slightly
better in countries reporting from Asia, where 89% of 100
clinics in 4 countries met the target. As ART is scaled up and
decentralized with increasing numbers of patients starting
ART at higher CD4 cell counts, strengthened drug forecasting,
procurement, and supply distribution must be prioritized to
prevent ARV stockouts.
EWI 8 directly measures VL suppression at 12 months, but
few clinics in our sample were able to monitor this EWI in-
dicating that capacity to perform VL testing remains limited
in the majority of settings monitored. As VL testing is scaled
up, it is anticipated that this indicator will become the cor-
nerstone of EWI monitoring. Individuals with suppressed VL
by definition are not failing due to HIVDR. Multiple studies
were identified reporting HIVDR outcomes after 12 months
ART in RLS. These include three randomised control trials
reporting the development of HIVDR in $ 70% patients with
virological failure [42, 43, 44].
Very few countries monitored pediatric EWIs, probably be-
cause the proportion of children on ART is a small fraction of
the adult ART patient population in most countries [8]. Despite
the low number of clinics monitored, most results are encour-
aging. As pediatric ART expands with early infant diagnosis and
the new WHO HIV treatment guidelines recommending
ART for all HIV-infected children ,24 months of age [45] re-
gardless of clinical or immunological conditions, the proportion
of children on ART will increase and the monitoring of pediatric
HIVDR EWIs should be prioritized in national HIV programs.
Monitoring of HIVDR EWIs is an important component of
global and national strategies to minimize the emergence ofTa
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preventable HIVDR. EWI monitoring identifies weaknesses at
the ART clinic and program level that may result in suboptimal
treatment or treatment interruptions in patients, potentially
causing HIVDR emergence. EWI monitoring also identifies
successful clinics that could serve as best practice models to
other clinics. Many countries have used EWI monitoring re-
sults to improve patient and clinic management.
EWI monitoring in several countries has highlighted
weaknesses in patient information systems resulting in the
inability to monitor specific EWIs such as EWI 4 and EWI 6.
Reported weaknesses in current data systems include in-
complete records, missing data, use of nonstandardized re-
cords, and intra- and interclinic variability in data recording. In
specific cases, limitations identified as a result of EWI moni-
toring have prompted improvements in medical and pharmacy
record keeping systems, including implementation of stan-
dardized records and data recording procedures [46].
Based on EWI results documenting high rates of patient loss
to follow-up, missed appointments, or failure to pick up ARVs
on time, countries worked to improve patient tracking mecha-
nisms. Improvements include reinforcing the capacity of ART
clinics to monitor patient referrals and follow-up with de-
faulters to minimize losses to follow-up. In Kenya, where none
of the 18 clinics monitored met the target for on-time ap-
pointment attendance for patients starting ART in 2007,
a community health worker system to track defaulters was
implemented in 2008. The Ministry of Health and Social
Services in Namibia, which identified migrant workers as
being at risk of treatment interruptions, has planned an in-
tensification of existing defaulter tracking systems through im-
provements in its electronic record keeping system, the
establishment of a national patient database with unique
identifiers, and increased mobilization and redistribution of
human resources [46].
In China, future pharmacy records will allow the calculation
of patients’ medication possession ratio [24], which will provide
a more accurate estimate of adherence. Pilot EWI results suggest
that further investigation into reasons for drug pickup delays
and increased operational research leading to adherence
support are warranted [47]. In Papua New Guinea, after
detailed discussions with clinic staff, important actions were
taken to strengthen ART services and improve clinic per-
formance: (1) establishment of a formalized referral system
that includes compulsory documentation of patient transfers
between clinics to ensure the transfer of medical records
between clinics and providers, (2) regular review of patient
clinic attendance and drug pickups for the purpose
of identifying patients at risk for suboptimal adherence to
ART and (3) identification of ways to remove barriers to on-
time pill pickup by providing subsidies for transportation
and food for those in need [48].
Several countries have implemented follow-up surveys to
assess factors influencing EWI results (WHO, unpublished
data). These surveys have investigated the influence of a range of
factors known to be associated with ART adherence, including
costs for treatment or drugs [12, 14, 16, 46], travel distances and
Figure 2. Percentage of adult clinics achieving the World Health Organization targets by early warning indicator (EWI) and region, with 95%
confidence intervals, 2004–2009. Abbreviation: LAC, Latin America and the Caribbean.
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lack of affordable transportation [20, 23, 24], long waiting
times at the pharmacy [20], and stigma [46], all of which are
important programmatic barriers to continuous ART access
in RLSs.
This global report of HIVDR EWI includes results from the
first country experiences with EWI monitoring and includes
countries with very different health systems and resource
availability that may have influenced their EWI findings. The
monitoring sample varied according to resources available, with
some countries sampling a small proportion of ART clinics
while others canvassed most or all of them. Regional and
global data were thus heavily influenced by country-specific
data; for example, Thailand’s EWI monitoring contributed
902 of 2107 adult clinics (43%) in this analysis, and 296 of 331
pediatric clinics (89%). In addition, in the first year of data
abstraction, clinic sampling was not representative of ART
clinics nationally. While these data are unlikely to represent
the countries or regions included, they provide background
on the prevalence of factors associated with HIVDR emer-
gence in ART patients. In 2011, EWI definitions, sampling and
targets were revised and further simplified by WHO. The new
guidance document and abstraction tools will be available on
the WHO HIVDR web site in 2012 (http://www.who.int/hiv/
topics/drugresistance/en/index.html).
CONCLUSIONS
This is the first global report on WHOHIVDR EWI monitoring
that summarizes results from 50 countries in .2000 clinics,
assessing .130 000 patients receiving ART in RLSs between
2004 and 2009. HIVDR EWI monitoring is the foundation of
global and national HIVDR surveillance activities in RLSs. It
provides evidence of how well ART clinics function to mini-
mize HIVDR and supports public health actions at both the
ART clinic and national program levels to improve the quality
of care for patients being treated. In addition, EWI results
provide the necessary local ART program context to interpret
laboratory-based surveys of transmitted and acquired HIVDR.
At present, WHO recommends that EWI data be abstracted
and analyzed by central teams coordinated by the Ministry of
Health. However, as clinics become more familiar with EWI
monitoring, it will be necessary for data abstraction, analysis,
and reporting to be performed directly by clinic staff in order to
achieve greater and routine implementation of EWIs.
If EWI results indicate challenges at a clinic, it is crucial that
these be assessed and addressed by clinic, district, and national
programmanagers. It will become increasingly apparent that the
EWI results are valuable for programmanagement and that EWI
monitoring should be integrated into routine clinic monitoring
to support quality assurance activities and optimization of
patient care.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases
online (http://www.oxfordjournals.org/our_journals/cid/). Supplemen-
tary materials consist of data provided by the author that are published
to benefit the reader. The posted materials are not copyedited. The
contents of all supplementary data are the sole responsibility of the
authors. Questions or messages regarding errors should be addressed to
the author.
Notes
Acknowledgments. The authors acknowledge the significant efforts of
Ministries of Health in the countries whose data are reported here, and the
National Health Security Office of Thailand. We also acknowledge the
support of Drs Sherri Pals and Drew Baughman of the Centers for Disease
Control and Prevention for statistical analyses.
Disclaimer. The conclusions and opinions expressed in this article are
those of the authors and do not reflect those of their respective organ-
izations, including the Centers for Disease Control and Prevention, the
US Department of Health and Human Services, and the World Health
Organization.
Financial support. EWI monitoring in countries was supported by
grants from The Bill & Melinda Gates Foundation (38180), the Public
Health Agency of Canada (6962-15-2008/8360001), the Spanish government
(AF/NAM/BBA/701/XU/08), the Global Fund to fight AIDS, Tuberculosis
and Malaria, the President’s Emergency Plan for AIDS Relief, the National
Institutes of Health (K23 AI074423-05 to M. R. J. and L30 AI080268-02 to S.
Y. H.), and the Lifespan/Tufts/Brown Center for AIDS Research (P30AI4853
to J. H. M.).
Supplement sponsorship. This article was published as part of a sup-
plement entitled ‘‘The World Health Organization HIV Drug Resistance
Prevention and Assessment Strategy: Global, Regional, and Country
Progress,’’ sponsored by The Bill & Melinda Gates Foundation (38180).
Potential conflicts of interest. All authors: No reported conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. UNAIDS. AIDS at 30: nations at a crossroad. Available at: http://
www.unaids.org/unaids_resources/aidsat30/aids-at-30.pdf. Accessed
10 June 2011.
2. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach
to antiretroviral treatment against HIV in resource-limited settings.
Lancet 2006; 368:505–10.
3. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical
considerations. Curr Opin HIV AIDS 2008; 3:653–9.
4. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in
a randomized trial of nucleoside, nonnucleoside and protease in-
hibitor-sparing regimens for initial HIV treatment. AIDS 2009;
23:1109–18.
5. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Anti-
retroviral therapy-associated toxicities in the resource-poor world: the
challenge of a limited formulary. J Infect Dis 2007; 196(Suppl 3):
S449–56.
6. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and
antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis
2006; 38:363–73.
7. Me´decins Sans Frontie`res. Untangling the web of antiretroviral price
reductions, special report. Available at: http://utw.msfaccess.org/.
Accessed 20 February 2012.
8. WHO/UNICEF/UNAIDS. Global HIV/AIDS Response: epidemic up-
date and health sector progress towards universal access. Available
HIVDR EWIs: 50-Country Summary Report d CID 2012:54 (Suppl 4) d S287
at: http://www.who.int/hiv/pub/progress_report2011/en/. Accessed
19 January 2012.
9. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health
Organization’s global strategy for prevention and assessment of HIV
drug resistance. Antivir Ther 2008; 13(Suppl 2):1–13.
10. Jordan MR. Assessments of HIV drug resistance mutations in resource-
limited settings. Clin Infect Dis 2011; 52:1058–60.
11. World Health Organization. HIV drug resistance early warning in-
dicators. World Health Organization indicators to monitor HIV drug
resistance prevention at antiretroviral treatment sites. June 2010 up-
date. Geneva, Switzerland: World Health Organization, 2010.
12. D’Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine,
and didanosine compared with zidovudine and didanosine in patients
with HIV-1 infection. A randomized, double-blind, placebo-controlled
trial. National Institute of Allergy and Infectious Diseases AIDS
Clinical Trials Group Protocol 241 Investigators. Ann Intern Med
1996; 124:1019–30.
13. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing
nucleoside monotherapy with combination therapy in HIV-infected
adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS
Clinical Trials Group Study 175 Study Team. N Engl J Med 1996;
335:1081–90.
14. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two
nucleoside analogues plus indinavir in persons with human immu-
nodeficiency virus infection and CD4 cell counts of 200 per cubic
millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl
J Med 1997; 337:725–33.
15. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to
zidovudine (AZT) isolated during prolonged therapy. Science 1989;
243:1731–4.
16. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial
comparing combinations of nevirapine, didanosine, and zidovudine
for HIV-infected patients: the INCAS Trial. Italy, the Netherlands,
Canada and Australia Study. JAMA 1998; 279:930–7.
17. Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to
improve adherence to antiretroviral therapy in HIV-infected South
African adults. A qualitative study. J Acquir Immune Defic Syndr 2006;
43(Suppl 1):S127–33.
18. Pasquet A, Messou E, Gabillard D, et al. Impact of drug stock-outs on
death and retention to care among HIV-infected patients on combi-
nation antiretroviral therapy in Abidjan, Cote d’Ivoire. PLoS One 2010;
5:e13414.
19. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment inter-
ruptions predict resistance in HIV-positive individuals purchasing
fixed-dose combination antiretroviral therapy in Kampala, Uganda.
AIDS 2007; 21:965–71.
20. Marcellin F, Boyer S, Protopopescu C, et al. Determinants of un-
planned antiretroviral treatment interruptions among people living
with HIV in Yaounde´, Cameroon (EVAL survey, ANRS 12-116). Trop
Med Int Health 2008; 13:1470–8.
21. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses
are the same: sustained NNRTI treatment interruptions predict
HIV rebound at low-to-moderate adherence levels. PLoS One 2008;
3:e2783.
22. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure
and resistance in HIV-infected patients treated with nevirapine- or
efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311–6.
23. Boyer S, Clerc I, Bonono CR, Marcellin F, Bile PC, Ventelou B.
Non-adherence to antiretroviral treatment and unplanned treat-
ment interruption among people living with HIV/AIDS in Came-
roon: individual and healthcare supply-related factors. Soc Sci Med
2011; 72:1383–92.
24. McMahon J, Jordan M, Kelley K, et al. Pharmacy adherence measures
to assess adherence to antiretroviral therapy: review of the literature
and implications for treatment monitoring. Clin Infect Dis 2011;
52:493–506.
25. Messou E, Chaix M-L, Gabillard D, et al. Association between med-
ication possession ratio, virologic failure and drug resistance in
HIV-1–infected adults on antiretroviral therapy in Cote d’Ivoire.
J Acquir Immune Defic Syndr 2011; 56:356–64.
26. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence
compared with CD4 count changes for monitoring HIV-infected
adults on antiretroviral therapy. PLoS Med 2008; 5:e109, Public
Library of Science.
27. Polisset J, Ametonou F, Arrive E, Aho A, Perez F. Correlates of ad-
herence to antiretroviral therapy in HIV-infected children in Lome,
Togo, West Africa. AIDS Behav 2009; 13:23–32.
28. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral
therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire.
AIDS 2004; 18:1905–13.
29. Bertagnolio S, Kelley K, Saadani Hassani A, Obeng-Aduasare Y, JordanM.
Surveillance of transmitted and acquired HIV drug resistance using
WHO surveys in resource-limited settings [abstract 52]. In: Programs
and abstracts of the 18th Conference on Retroviruses and Opportu-
nistic Infections. Boston, MA: CROI, 2011.
30. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation
of nevirapine alone and in combination with zidovudine for infection
with human immunodeficiency virus. J Acquir Immune Defic Syndr
Hum Retrovirol 1995; 8:141–51.
31. Jack N, Ravasi G, SchrootenW. Implementing early-warning indicators
of HIV drug resistance in the Caribbean. Clin Infect Dis 2012;
54(Suppl 4):S290–3.
32. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N,
Weiser SD. Transportation costs impede sustained adherence and ac-
cess to HAART in a clinic population in southwestern Uganda:
a qualitative study. AIDS Behav 2010; 14:778–84.
33. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral
adherence for patients living with HIV infection and AIDS in Bot-
swana. J Acquir Immune Defic Syndr 2003; 34:281–8.
34. Brigido LF, Rodrigues R, Casseb J, et al. Impact of adherence to anti-
retroviral therapy in HIV-1-infected patients at a university public
service in Brazil. AIDS Patient Care STDs 2001; 15:587–93.
35. Muko KN, Ngwa VC, Chigang LC, Ngwa IG, Meiburg A, Shu EN.
Willingness to pay for treatment with highly active antiretroviral
(HAART) drugs: a rural case study in Cameroon. SAHARA J 2004;
1:107–13.
36. Harvey KM, Carrington D, Duncan J, et al. Evaluation of adherence to
highly active antiretroviral therapy in adults in Jamaica. West Indian
Med J 2008; 57:293–7.
37. Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence: quali-
tative findings from HIVpositive individuals purchasing fixed-dose
combination generic HIV antiretroviral therapy in Kampala, Uganda.
AIDS Behav 2006; 10:437–42.
38. Chalker JC, Andualem T, Gitau LN, et al. Measuring adherence to
antiretroviral treatment in resource-poor settings: the feasibility of
collecting routine data for key indicators. BMC Health Serv Res 2010;
10:43.
39. Pearson CR, Micek M, Simoni JM, Matediana E, Martin DP, Gloyd S.
Modified directly observed therapy to facilitate highly active antiretro-
viral therapy adherence in Beira, Mozambique. Development and im-
plementation. J Acquir Immune Defic Syndr 2006; 43(Suppl 1):S134–41.
40. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART:
a systematic review of developed and developing nation patient-
reported barriers and facilitators. PLoS Med 2006; 3:e438.
41. White YR, Pierre RB, Steel-Duncan J, et al. Adherence to antiretroviral
drug therapy in children with HIV/AIDS in Jamaica. West Indian Med
J 2008; 57:231–7.
42. Bussmann H, Wester CW, Thomas A, et al. Response to zidovudine/
didanosine-containing combination antiretroviral therapy among
HIV-1 subtype C-infected adults in Botswana: two-year outcomes from
a randomized clinical trial. Journal of Acquired Immune Deficiency
Syndromes: JAIDS 2009; 51:37–46.
S288 d CID 2012:54 (Suppl 4) d Bennett et al
43. Lyagoba F, Dunn DT, Pillay D, et al. Evolution of drug resistance
during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of
real-time viral load monitoring. Journal of Acquired Immune De-
ficiency Syndromes: JAIDS 2010; 55:277–83.
44. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence
of drug resistance in the absence of viral load testing: a randomized
comparison between zidovudine-lamivudine plus Nevirapine and zi-
dovudine-lamivudine plus Abacavir. J Infect Dis 2010; 201:106–13.
45. World Health Organization. Antiretroviral therapy of HIV infection in
infants and children: towards universal access: recommendations for
a public health approach - 2010 revision. Available at: http://www.who.
int/hiv/pub/paediatric/infants2010/en. Accessed 20 May 2011.
46. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of in-
complete adherence, virologic failure, and antiviral drug resistance
among HIV-infected adults receiving antiretroviral therapy in Tanzania.
Clin Infect Dis 2007; 45:1492–8.
47. Ma Y, Zhang F, Li H. Monitoring HIV drug resistance using early
warning indicators in China: results from a pilot survey conducted in
2008. Clin Infect Dis 2012; 54(Suppl 4):S300–2.
48. Daoni E, Kitur U, Parunga A. Experience in piloting HIV drug re-
sistance early warning indicators to improve the antiretroviral program
in Papua New Guinea. Clin Infect Dis 2012; 54(Suppl 4):S303–5.
HIVDR EWIs: 50-Country Summary Report d CID 2012:54 (Suppl 4) d S289
